Jefferies upgraded Vera Therapeutics (VERA) to Buy from Hold with a price target of $26, up from $18. The analyst says investor and key onionin leader sentiment have shifted with a focus more on drugs that can stabilize kidney function in IgA nephropathy. Both Otsuka and Alpine Immune Sciences (ALPN) competitor data have “derisked” the mechanism for Vera’s atacicept and reinforced confidence in B-cell modulator drugs, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERA:
- Vera Therapeutics reports Q3 EPS (45c), consensus (54c)
- Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
- Vera Therapeutics presents data from Phase 2b ORIGIN study
- Vera Therapeutics presents ‘positive’ atacicept data from Phase 2b ORIGIN study
- Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
